⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
VYNE News
VYNE Therapeutics Inc. Common Stock
Form 8-K
sec.gov
VYNE
Form 8-K
sec.gov
VYNE
Yarrow Bioscience Announces Closing of Merger with VYNE Therapeutics and Initiation of Dosing in Phase 2a/2b Trial of YB-101, a Potential First-in-Class Treatment for Graves’ Disease and Thyroid Eye Disease
businesswire.com
YARW
VYNE
VYNE Therapeutics Provides Update Regarding Cash Dividend, Reverse Stock Split and Anticipated Timing of Closing of the Proposed Merger with Yarrow Bioscience
globenewswire.com
VYNE
Form 8-K
sec.gov
VYNE
VYNE Therapeutics Announces 1-for-50 Reverse Stock Split and Provides Update Regarding Special Dividend in Connection with the Proposed Merger with Yarrow Bioscience
globenewswire.com
VYNE
Form 8-K
sec.gov
VYNE
Form 8-K
sec.gov
VYNE
Form 8-K
sec.gov
VYNE
VYNE Therapeutics Declares Special Cash Dividend in Connection with the Proposed Merger with Yarrow Bioscience
globenewswire.com
VYNE